Therapeutic use of psilocybin: Practical considerations for dosing and administration

Interest in psilocybin as a therapeutic agent has expanded rapidly in recent years after a long period of restricted research and access dating back to the 1960s. Psilocybin, the principal psychoactive compound in several Psilocybe mushroom species, has a long history of traditional use in Mesoamerican cultures and has re-emerged in Western medicine following encouraging results from clinical trials in areas such as cancer-related distress and treatment-resistant depression. Regulatory shifts — for example, the US Food and Drug Administration granting breakthrough therapy status for psilocybin in 2018–2019, and changes to access pathways in jurisdictions such as Oregon and Canada — have increased demand for practical clinical guidance for health care professionals (HCPs). Blest-Hopley and colleagues set out to provide HCPs with an accessible, safety‑focused overview of practical considerations for psilocybin-assisted psychotherapy (PAP). The paper reviews basic pharmacology and pharmacokinetics, summarizes current evidence for therapeutic indications, and offers practical recommendations on dosing, administration, monitoring, contraindications, drug–drug interactions, and adverse events. The authors emphasise the need for clinicians to be prepared to discuss psilocybin with patients as legal and decriminalisation landscapes evolve, and note that non‑medical models of access exist alongside medical pathways but are not the primary focus of this manuscript.

Pharmacology: Psilocybin is a phosphorylated tryptamine prodrug whose active metabolite is psilocin. Psilocin is lipophilic and crosses the blood–brain barrier to act as a non‑specific partial agonist at several serotonergic receptors, with particularly high affinity for the 5‑hydroxytryptamine 2A (5‑HT2A) receptor. The psychedelic subjective effects are attributed to functionally selective (biased) agonism at 5‑HT2A, which favours downstream signalling cascades that increase glutamate release and may modulate neuroplasticity, including pathways involving brain‑derived neurotrophic factor (BDNF). 5‑HT2A expression in visual cortex is linked to characteristic visual phenomena; blockade of 5‑HT2A receptors (for example with ketanserin) attenuates these effects. Other receptor sites such as 5‑HT1A and 5‑HT2C may contribute to psilocin’s effects, but their roles are less well defined. Pharmacokinetics: After oral ingestion, psilocybin is rapidly dephosphorylated to psilocin in the stomach and subsequently in intestines, blood and kidneys via alkaline phosphatase. Bioavailability is approximately 50% and plasma detection occurs within 20–40 minutes. Psilocin shows a typical subjective time course: onset 20–40 minutes, peak effects at 60–90 minutes, and an active duration of roughly 4–6 hours. Half‑life estimates for unconjugated psilocin vary across studies; a recent fixed 25 mg dosing study reported a mean t1/2 of about 108 minutes (range 66–132 minutes). After a 25 mg oral dose reported Cmax values are around 18.7–20 ng/mL with Tmax near 120 minutes. Metabolism is dominated by hepatic phase II glucuronidation via UGT1A10 and UGT1A9, producing an inactive psilocin‑O‑glucuronide that is renally cleared (approximately 80% of circulating psilocin). Other minor metabolic routes account for roughly 20% of clearance, with most psilocin excreted within 24 hours and the bulk in the first 8 hours. Interindividual variability in pharmacokinetics is noted and was not predicted by body weight in cited work. Therapeutic evidence: The strongest clinical-trial evidence for psilocybin is in cancer‑related depression and anxiety and in treatment‑resistant depression. Moderate‑level evidence exists from several trials for alcohol use disorder and tobacco addiction. Preliminary or proof‑of‑concept data suggest potential utility in obsessive–compulsive disorder, cluster headache and migraine, and demoralisation associated with HIV/AIDS. Ongoing clinical trials are exploring a wide range of conditions including other addictions, anorexia, bipolar disorder, chronic pain and major depressive disorder. Dosing and administration strategies: Early trials commonly used weight‑based dosing (about 0.2–0.4 mg/kg), often with one or two sessions separated by approximately 3–4 weeks. Contemporary protocols more frequently use a fixed 25 mg oral psilocybin dose, which corresponds roughly to earlier weight‑based regimens (about 0.3 mg/kg). Secondary analyses reported no significant differences in psychedelic effects when comparing fixed 25 mg with weight‑based doses. For patients with mild–moderate renal impairment a dose reduction is generally not required because the primary renal excretion product is an inactive glucuronide. When using dried Psilocybe cubensis mushrooms as an unregulated source, average psilocybin content is approximately 1% by weight, so a 25 mg psilocybin dose equates to roughly 2.5 g of dried material; however, species and batch variability are substantial (reported ranges about 0.5–2%), and clinicians are advised to start conservatively in naïve users. Therapeutic model: Administration of psilocybin is intended to occur alongside assisted psychotherapy comprising three phases: pretreatment (rapport building and preparation emphasising 'set and setting'), treatment (non‑directive, supportive session with adjuncts such as music, meditation and breathwork), and posttreatment (integration of the experience). Detailed psychotherapy protocols are beyond this paper’s scope, but the authors reiterate that psychological preparation and monitoring are central to minimising harms and maximising benefit. Contraindications: The principal contraindications relate to increased risk of psychological harm. A history of schizophrenia, primary psychotic disorders, bipolar disorder and borderline personality disorder are generally considered contraindications, although the authors note that future observational data may refine risk–benefit estimates. Pregnancy and breastfeeding are contraindicated owing to insufficient safety data. Serious or uncontrolled cardiovascular disease is typically a relative contraindication given transient post‑dose increases in heart rate and blood pressure. Drug interactions: Concomitant psychotropic medications can affect both safety and efficacy through pharmacodynamic and pharmacokinetic mechanisms. Because psilocin acts primarily at serotonergic receptors, interactions with antidepressants and antipsychotics are important to consider. Tricyclic antidepressants may potentiate the subjective intensity, while monoamine oxidase inhibitors and selective serotonin reuptake inhibitors may blunt psychedelic effects. There is a theoretical risk of serotonin syndrome when combining serotonergic agents, though published cases are scarce; many trial protocols require tapering and washout of interacting agents. One recent study cited reported no additional safety concerns or loss of efficacy when patients remained on an SSRI, indicating this area warrants further study. On the pharmacokinetic side, inhibition or induction of UGT1A10/1A9 (psilocin’s main conjugating enzymes) can alter psilocin levels; examples of inhibitors include diclofenac and probenecid, which should be held or adjusted. The authors recommend a thorough medication review and individualised taper strategies when needed, with monitoring for discontinuation syndromes. Adverse events and safety profile: Psilocybin has a wide therapeutic index (reported here as 1:1000) and a generally favourable safety profile relative to other classic psychedelics. It lacks known addictive or reinforcing properties and shows lower rates of seizures and hospital admissions compared with some other agents. Dose‑escalation studies up to 50–60 mg have reported limited safety concerns under controlled conditions. The primary risks are psychological rather than physiological: acute psychotomimetic effects can produce distress and, in rare cases, precipitate psychosis. Common transient events observed in trials include increases in blood pressure and heart rate, anxiety during sessions, and post‑session headaches. In properly screened and monitored clinical trials, no serious adverse events were reported in the material presented. Tables referred to in the text summarise adverse events but are not available in the extracted text.

Blest-Hopley and colleagues conclude that as psilocybin access and interest expand, HCPs need a baseline level of knowledge about its pharmacology, indications and safety considerations to guide patient discussions and care. Educating clinicians is framed as important both for individual patient safety and to inform policymakers developing regulation and guidance. The authors endorse the development of health care education and clinical pathways to ensure safe, informed use of psilocybin in medical contexts.